ROCKVILLE, Md., Aug. 6, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its second quarter financial results for the three month period ended June 27, 2009. The Company reported a net loss from continuing operations of $5.8 million, or $0.11 per share, compared to a net loss of $5.7 million, or $0.11 per share, for the period ended June 28, 2008. Including results from discontinued operations, Nabi had a net loss of $5.8 million, or $0.11 per share, for the current period compared to a net loss of $3.7 million, or $0.07 per share in the second quarter of 2008. The 2008 results have been adjusted to reflect the retrospective application of FSP 14-1 accounting rules for convertible debt instruments that were adopted in the first quarter of 2009.
